AdaptHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AdaptHealth Corp. on May 21, 2020. The filing discloses material changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- New CFO Base Salary: $425,000 annually.
- Target Annual Bonus: 75% of base salary.
- Start Date Bonus: $150,000 (one-time, subject to recoupment).
- Equity Grant: Restricted shares valued at $1,000,000 (based on 20-day VWAP prior to commencement).
- Car Allowance: $1,000 per month.
Material Changes
Executive Departure: Gregg Holst, current CFO, will retire effective September 1, 2020. He will remain in an advisory role until that date.
Executive Appointment: Jason A. Clemens will succeed Mr. Holst as CFO effective August 3, 2020. Mr. Clemens previously served as Senior Vice President and Operations CFO at MEDNAX, Inc. since April 2012.
Outlook, Risks, and Contingencies
Severance Provisions: If Mr. Clemens is terminated without "cause" or resigns for "good reason" after 90 days, he is entitled to 12 months of base salary, continued benefits, and a pro-rated target bonus.
Restrictions: Mr. Clemens is subject to non-competition and non-solicitation restrictions during employment and for one year thereafter, along with an indefinite non-disparagement provision.
Recoupment: The $150,000 start date bonus is subject to recoupment if Mr. Clemens resigns without "good reason" or is terminated for "cause" within 90 days of his start date.
Investor Verification Checklist
- Verify the exact commencement date of Jason A. Clemens to calculate the precise number of restricted shares granted.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Confirm the transition plan for the CFO role between August 3, 2020, and September 1, 2020.
- Assess the impact of the $150,000 start bonus and $1,000,000 equity grant on near-term compensation expenses.